27.9 C
New York
Monday, June 15, 2026

Tag: society

Ping An Ranks 47th on 2025 Fortune Global 500 List, Marking 16th Year on List

HONG KONG and SHANGHAI, July 30, 2025 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An", the "Company" or the "Group", HKEX:...

HIMSS partners with WHX Tech to advance digital health transformation in the Middle East

DUBAI, UAE, July 30, 2025 /PRNewswire/ -- The Healthcare Information and Management Systems Society (HIMSS) will deliver world-class content, professional development and roadmaps for digital health...

WePlay Partners with Japanese Animal Welfare Organizations to Launch Stray Animal Rescue Initiative

TOKYO, July 30, 2025 /PRNewswire/ -- WePlay, the next-generation global social entertainment platform, officially announced a deep charitable partnership with the renowned Japanese animal...

Vexev and U.S. Renal Care Complete Enrollment in Groundbreaking Trial Evaluating Use of Robotic Ultrasound Scanning for AV Fistula Mapping in Dialysis Clinics

CANSCAN study enrolled 120 patients with chronic kidney disease using the investigational, semi-autonomous VxWave™ Ultrasound Imaging SystemThe VxWave Ultrasound Imaging System potentially provides important insights...

Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved...

Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved...

Progress on share buyback programme

Progress on share buyback programme

Amundi: First half and second quarter 2025 results

Amundi: First half and second quarter 2025 results

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States.1

New ETC report demonstrates that wind and solar-dominant power systems are competitive, reliable, and technically and economically feasible

LONDON, July 29, 2025 /PRNewswire/ -- The Energy Transitions Commission (ETC) has today published a landmark report, Power Systems Transformation: Delivering Competitive, Resilient Electricity...

New ETC report demonstrates that wind and solar-dominant power systems are competitive, reliable, and technically and economically feasible

LONDON, July 29, 2025 /PRNewswire/ -- The Energy Transitions Commission (ETC) has today published a landmark report, Power Systems Transformation: Delivering Competitive, Resilient Electricity...

Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by Advances in Neurodegenerative Therapies | DelveInsight

No alpha-synuclein inhibitors are approved, underscoring a major need for therapies that slow or halt Parkinson's progression. Developing safe, brain-penetrant drugs that target toxic...

In Celebration of Tony Bennett’s Birthday, CARNEGIE HALL+ Announces the Streaming Premiere of BECAUSE OF YOU, Michael Feinstein’s Concert Tribute to Tony Bennett, Beginning...

Special streaming premiere of performance featuring the Carnegie Hall Big Band, filmed on tour at Segerstrom Center for the Arts, available for the first...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSociety